Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Takeda
ClinicalTrials.gov Identifier:
NCT00653185
First received: April 1, 2008
Last updated: May 18, 2012
Last verified: May 2012
  Purpose

The purpose of this study is to determine the efficacy, safety and tolerability of SYR-472, once daily (QD), in subjects with Type 2 Diabetes Mellitus.


Condition Intervention Phase
Diabetes Mellitus
Drug: SYR-472
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate Weekly Treatment With SYR-472 in Subjects With Type 2 Diabetes

Resource links provided by NLM:


Further study details as provided by Takeda:

Primary Outcome Measures:
  • Change from baseline in glycosylated hemoglobin [ Time Frame: Weeks 12 or Final Visit. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change from baseline in glycosylated hemoglobin [ Time Frame: Weeks 4, 8, and 12 or Final Visit. ] [ Designated as safety issue: No ]
  • Change from baseline in fasting plasma glucose [ Time Frame: Weeks 1, 2, 4, 8, and 12 or Final Visit. ] [ Designated as safety issue: No ]
  • 1,5-Anhydroglucitol [ Time Frame: Weeks 2, 4, 8, and 12 or Final Visit. ] [ Designated as safety issue: No ]
  • Change in Proinsulin [ Time Frame: Weeks 4, 8, and 12 or Final Visit. ] [ Designated as safety issue: No ]
  • Change in Proinsulin/insulin ratio [ Time Frame: Weeks 4, 8, and 12 or Final Visit. ] [ Designated as safety issue: No ]
  • Change in baseline C-peptide [ Time Frame: Weeks 4, 8, and 12 or Final Visit. ] [ Designated as safety issue: No ]
  • Change from baseline in insulin [ Time Frame: Weeks 4, 8, and 12 or Final Visit. ] [ Designated as safety issue: No ]
  • Change in Homeostasis model assessment of beta cell function [ Time Frame: Weeks 4, 8, and 12 or Final Visit. ] [ Designated as safety issue: No ]
  • Change in Homeostasis model assessment of insulin resistance [ Time Frame: Weeks 4, 8, and 12 or Final Visit ] [ Designated as safety issue: No ]
  • Incidence of rescue [ Time Frame: Weeks 1, 2, 4, 8, and 12 or Final Visit. ] [ Designated as safety issue: No ]
  • Clinical response endpoint incidence of glycosylated hemoglobin less than or equal to 6.5% [ Time Frame: Week 12 or Final Visit ] [ Designated as safety issue: No ]
  • Clinical response endpoint incidence of glycosylated hemoglobin less than or equal to 7.0% [ Time Frame: Week 12 or Final Visit ] [ Designated as safety issue: No ]
  • Change from baseline in Fasting lipids (triglycerides, total cholesterol, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol) [ Time Frame: Weeks 4, 8, and 12 or Final Visit ] [ Designated as safety issue: No ]
  • Body weight [ Time Frame: Weeks 4, 8, and 12 or Final Visit. ] [ Designated as safety issue: No ]

Enrollment: 369
Study Start Date: May 2007
Study Completion Date: March 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SYR-472 25 mg QD
(with lifestyle modification and/or metformin therapy)
Drug: SYR-472
SYR-472 25 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
Experimental: SYR-472 50 mg QD
(with lifestyle modification and/or metformin therapy)
Drug: SYR-472
SYR-472 50 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
Experimental: SYR-472 100 mg QD
(with lifestyle modification and/or metformin therapy)
Drug: SYR-472
SYR-472 100 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
Experimental: SYR-472 200 mg QD
(with lifestyle modification and/or metformin therapy)
Drug: SYR-472
SYR-472 200 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
Placebo Comparator: Placebo QD
(with lifestyle modification and/or metformin therapy)
Drug: Placebo
SYR-472 placebo-matching tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.

Detailed Description:

Type 2 diabetes mellitus is a complex metabolic disorder characterized by abnormal insulin secretion and glucose homeostasis, resulting from impaired pancreatic beta-cell function and insulin resistance in target tissues. The worldwide prevalence of type 2 diabetes mellitus is reaching epidemic proportions, and the total number of cases is expected to reach 221 million by 2010. The high incidence of the disease and its associated complications places a significant burden on healthcare systems.

The primary risk factor for the development of type 2 diabetes mellitus is obesity and its associated insulin resistance. Insulin resistance is characterized by an impaired response to the physiologic effects of insulin and leads to decreased cellular glucose uptake, increased hepatic gluconeogenesis, and a compensatory increase in insulin secretion that contributes to beta-cell exhaustion. Therefore in the insulin-resistant state, blood glucose and insulin levels are increased. The relationship between improved glycemic control in patients with type 2 diabetes mellitus and the delay or prevention of comorbidities has been reported in the Diabetes Control and Complications Trial and the United Kingdom Prospective Diabetes Study. Therefore, reduction of persistent hyperglycemia is the highest priority in treating this disease.

Diet and exercise are important and effective measures for maintaining glycemic control in individuals with insulin resistance, impaired glucose tolerance, and type 2 diabetes mellitus, particularly in the early stages of disease progression. In cases where diet and exercise alone fail to adequately maintain glycemic control, oral antidiabetic drugs are typically used. Combination oral therapy and eventually insulin are usually required to maintain lower blood glucose levels but can result in adverse effects including hypoglycemia and weight gain. Therefore, novel safe and effective antidiabetic therapies are needed.

Dipeptidyl peptidase-4 is a ubiquitous aminopeptidase that is widely expressed in many tissues; it is thought to be primarily responsible for the in vivo degradation of at least two gut-derived incretin hormones, namely glucagon-like peptide-1 and glucose-dependent insulinotropic peptide, which are both released in response to nutrient ingestion. Glucagon-like peptide-1 has been demonstrated to augment glucose-dependent insulin secretion; suppress glucagon release and hepatic gluconeogenesis; inhibit gastric emptying, and reduce appetite and food intake. Glucagon-like peptide-1 and glucose-dependent insulinotropic peptide also have been shown to promote insulin biosynthesis and stimulate beta cell proliferation and survival. Orally available inhibitors of dipeptidyl peptidase-4 activity have been developed that increase intact postprandial glucagon-like peptide-1 levels after oral administration.

SYR-472 is a selective inhibitor of dipeptidyl peptidase-4 in development to improve glycemic control in patients with type 2 diabetes mellitus. The aim of this study is to evaluate SYR-472 in subjects with type 2 diabetes mellitus who have not previously achieved adequate glycemic control with lifestyle modification (diet/exercise) or metformin antidiabetic monotherapy. Study participation is anticipated to be up to 14 weeks.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Has a historical diagnosis of type 2 diabetes mellitus.
  • Has undergone less than 7 days of any antidiabetic therapy except lifestyle modification (diet/exercise) within 8 weeks prior to Screening; or has received metformin monotherapy for at least 8 weeks prior to Screening and maintained a stable daily dose of metformin for at least 12 weeks prior to randomization.
  • The subject receiving metformin monotherapy at randomization must have been at least 75% compliant with his or her regimen during the Run-in/Stabilization Period as determined by subject diary and investigator assessment.
  • Has received no treatment with antidiabetic agents other than metformin within the 8 weeks prior to Screening.
  • Has a glycosylated hemoglobin concentration between 7.0% and 10.0%, inclusive, at Screening and at the Week -1 Visit.
  • The subject's fasting C-peptide concentration is greater than or equal to 0.8 ng/mL.
  • Has a fasting plasma glucose concentration less than 275 mg/dL.
  • If regularly uses other non-excluded medications, must be on a stable dose for at least the 4 weeks prior to Screening.
  • Has a systolic blood pressure reading less than 160 mm Hg and a diastolic pressure reading less than 100 mm Hg.
  • Has a hemoglobin value greater than or equal to 12 g/dL for men and greater than or equal to 10 g/dL for women.
  • Has an alanine aminotransferase level is less than or equal to 3 times the upper limit of normal.
  • Males have a serum creatinine value less than 1.5 mg/dL; females have a serum creatinine value less than 1.4 mg/dL.
  • Has a urine albumin/creatinine ratio less than 1000 μg/mg.
  • Has a thyroid-stimulating hormone level less than or equal to the upper limit of the normal range and is clinically euthyroid.
  • Females must be not be pregnant or lactating, and must agree to use adequate contraception throughout the duration of the study.
  • Is able and willing to monitor his or her own blood glucose concentrations with a home glucose monitor.
  • Has no major illness or debility that in the investigator's opinion prohibits the subject from completing the study.

Exclusion Criteria

  • Is being concurrently treated with antidiabetic therapy other than metformin and lifestyle intervention.
  • Has a history of cancer, other than squamous cell or basal cell carcinoma of the skin that has not been in full remission for at least 5 years prior to Screening.
  • Has a history of laser treatment for proliferative diabetic retinopathy within the 6 months prior to Screening.
  • Has a history of treated diabetic gastric paresis.
  • Has New York Heart Association class III or IV heart failure regardless of therapy.
  • Has a history of coronary angioplasty, underwent coronary stent placement or coronary bypass surgery, or suffered a myocardial infarction, or stroke within the 6 months prior to Screening.
  • Has a history of any hemoglobinopathy that may affect determination of glycosylated hemoglobin.
  • Has a history of infection with human immunodeficiency virus.
  • Has a history of a psychiatric disorder that in the investigator's opinion will affect the subject's ability to participate in the study.
  • Has ingested or received systemically injected glucocorticoids within the 3 months prior to randomization. Inhaled corticosteroids are allowed.
  • Has used prescription or over-the-counter weight-loss drugs within the 3 months prior to randomization.
  • Has received any investigational drug within the 30 days prior to Screening or has received an investigational antidiabetic drug within the 3 months prior to Screening.
  • Has received previous treatment in an investigational study of SYR-472.
  • Has a known hypersensitivity to any compound related to SYR-472.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00653185

  Show 87 Study Locations
Sponsors and Collaborators
Takeda
Investigators
Study Director: Medical Director Takeda
  More Information

No publications provided

Responsible Party: Takeda
ClinicalTrials.gov Identifier: NCT00653185     History of Changes
Other Study ID Numbers: 01-06-TL-SYR-472-007, U1111-1124-2377
Study First Received: April 1, 2008
Last Updated: May 18, 2012
Health Authority: United States: Food and Drug Administration
Czech Republic: State Institute for Drug Control
Hungary: National Institute of Pharmacy
Latvia: State Agency of Medicines
Lithuania: State Medicine Control Agency - Ministry of Health
Romania: National Medicines Agency
Russia: Ministry of Health of the Russian Federation
Slovakia: State Institute for Drug Control
Ukraine: Ministry of Health
Chile: Instituto de Salud Pública de Chile

Keywords provided by Takeda:
Glucose Metabolism Disorder
Dysmetabolic Syndrome
Type II Diabetes
Diabetes Mellitus, Lipoatrophic
Dyslipidemia
Hyperglycemia

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on July 26, 2014